Summary
Edwards Lifesciences Corporation's (EW) Q2 2018 10-Q filing shows robust top-line growth, with total net sales increasing by 12.1% to $943.7 million for the quarter and 6.6% to $1,838.5 million for the six months ended June 30, 2018, compared to the prior year periods. This growth was primarily driven by strong performance in the Transcatheter Heart Valve Therapy (THVT) segment, particularly the Edwards SAPIEN 3 valve, and an increase in Critical Care products. The company also benefited from favorable foreign currency exchange rates, which contributed significantly to international sales growth. The company continues to invest heavily in research and development, with R&D expenses increasing as a percentage of net sales, reflecting a commitment to innovation in structural heart programs and clinical trials. Financially, net income saw a substantial increase, driven by solid operating performance, a benefit from tax audit settlements, and adjustments related to the Tax Cuts and Jobs Act of 2017. While gross profit margins were impacted by foreign exchange fluctuations and operational investments, they were partially offset by an improved product mix. The company maintains a strong liquidity position with significant cash and cash equivalents. Management believes existing resources are sufficient to meet short-term obligations, capital expenditures, and financial commitments. However, the company is also actively engaged in legal proceedings, primarily related to patent infringement disputes with Boston Scientific, which present ongoing risks and potential impacts on financial results.
Financial Highlights
54 data points| Revenue | $943.70M |
| Cost of Revenue | $246.20M |
| Gross Profit | $697.50M |
| R&D Expenses | $154.10M |
| SG&A Expenses | $274.90M |
| Operating Income | $252.10M |
| Interest Expense | $0 |
| Net Income | $282.70M |
| EPS (Basic) | $0.45 |
| EPS (Diluted) | $0.44 |
| Shares Outstanding (Basic) | 628.50M |
| Shares Outstanding (Diluted) | 642.00M |
Key Highlights
- 1Total net sales increased by 12.1% to $943.7 million in Q2 2018 and 6.6% to $1,838.5 million for the first six months of 2018.
- 2Transcatheter Heart Valve Therapy (THVT) sales showed strong growth of 20.0% in Q2 2018, primarily driven by the Edwards SAPIEN 3 valve.
- 3Critical Care product sales increased by 14.5% in Q2 2018, boosted by the HemoSphere platform and core hemodynamic products.
- 4Net income significantly increased due to improved operating performance, tax benefits from audit settlements, and adjustments related to the Tax Cuts and Jobs Act.
- 5Research and Development (R&D) expenses increased as a percentage of net sales, reflecting continued investment in structural heart programs and clinical trials.
- 6The company has a strong liquidity position, with $1.226 billion in cash and cash equivalents as of June 30, 2018.
- 7Edwards Lifesciences is involved in ongoing patent infringement litigation with Boston Scientific, which could materially impact future financial results.